EMA Clarifies New Variation Classification Categories - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Clarifies New Variation Classification Categories


The European Medicines Agency (EMA), in agreement with the European Commission, has released an updated question and answer document clarifying a number of issues related to the new categories of variations to the terms of marketing authorizations that were introduced by the agency in August 2013. The Commission guidelines on variations to marketing authorizations of medicinal products were amended in 2013. The revision of the variations guidelines was initiated by the pharmacovigilance legislation.

The following clarifications were made to the Q&A document:

  • “The submission of pediatric studies under article 46 of the European pediatric regulation is to be handled as a post-authorization measure if the marketing-authorization holder confirms that they deem no changes to the product information necessary; an implementing variation category C.1.3 is triggered only when amendments to the product information are identified following assessment by the agency’s Committee for Medicinal Products for Human Use (CHMP). In cases where the marketing-authorization holder identifies the need to update the product information based on the data of the P46 study at the time of submission, a variation category C.1.4 needs to be applied for;
  • “The submission of environmental risk assessment (ERA) for medicines for human use will be handled as type IB variations and not as type II variations since these reports do not contain information affecting the quality, safety and efficacy of the medicines;
  • “The request by a marketing authorization holder to amend the due dates of the conditions of a marketing authorization or of measures in a risk management plan is to be handled as a type IB variation.”

EMA will apply the changes, which concern centrally authorized products only, retrospectively from Jan. 1, 2014.

 

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here